Actively Recruiting
Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
Led by M.D. Anderson Cancer Center · Updated on 2026-04-02
25
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
G
GE Healthcare
Collaborating Sponsor
AI-Summary
What this Trial Is About
To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.
CONDITIONS
Official Title
Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Approved for Pluvicto therapy and have renal complications or compromised bone marrow function
- Renal complication defined as GFR between 30-50 ml/min or creatinine up to two times the upper normal limit
- Compromised marrow function indicated by low white blood cell count or platelet count within specified ranges
- Agree to multiple imaging sessions as defined by the study protocol
You will not qualify if you...
- Receiving Pluvicto therapy without renal or bone marrow complications
- Unwilling to undergo multiple imaging scans required by the protocol
- Women and children (since this treatment is for prostate cancer)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
G
Guofan Xu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here